143 related articles for article (PubMed ID: 35769632)
1. Perceptions of HIV cure and willingness to participate in HIV cure-related trials among people enrolled in the Netherlands cohort study on acute HIV infection.
van Paassen P; Dijkstra M; Peay HL; Rokx C; Verbon A; Reiss P; Prins JM; Henderson GE; Rennie S; Nieuwkerk PT; de Bree GJ
J Virus Erad; 2022 Jun; 8(2):100072. PubMed ID: 35769632
[TBL] [Abstract][Full Text] [Related]
2. Perceptions of Rapid Antiretroviral Therapy Initiation Among Participants of The Netherlands Cohort Study on Acute HIV Infection.
van Paassen P; Dijkstra M; Peay HL; Rokx C; Verbon A; Reiss P; Prins JM; Henderson GE; Rennie S; Nieuwkerk PT; de Bree GJ
AIDS Res Hum Retroviruses; 2024 May; 40(5):286-292. PubMed ID: 37791419
[TBL] [Abstract][Full Text] [Related]
3. Understanding participant perspectives around HIV-1 cure-related studies involving antiretroviral analytical treatment interruptions in the United Kingdom.
Lee MJ; Godakandaarachchi P; Collins S; Racz M; Sharp A; Fidler S; Fox J
J Virus Erad; 2023 Dec; 9(4):100360. PubMed ID: 38188642
[TBL] [Abstract][Full Text] [Related]
4. "I Know That I Was a Part of Making a Difference": Participant Motivations for Joining a Cure-Directed HIV Trial with an Analytical Treatment Interruption.
Neergaard R; Jones NL; Roebuck C; Rendle KA; Barbati Z; Peterson B; Tebas P; Mounzer K; Metzger D; Montaner LJ; Dube K; Barg FK
AIDS Res Hum Retroviruses; 2023 Aug; 39(8):414-421. PubMed ID: 35979886
[TBL] [Abstract][Full Text] [Related]
5. Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States.
Bilger A; Plenn E; Barg FK; Rendle KA; Carter WB; Lamour-Harrington A; Jones N; Peterson B; Sauceda JA; Tebas P; Mounzer K; Metzger D; Montaner LJ; Dubé K
HIV Res Clin Pract; 2023 Oct; 24(1):2267825. PubMed ID: 37837376
[TBL] [Abstract][Full Text] [Related]
6. Participant experiences in a combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States.
Dubé K; Ndukwe SO; Korolkova A; Dee L; Sugarman J; Sauceda JA
HIV Res Clin Pract; 2024 Jan; 25(1):2312318. PubMed ID: 38348830
[TBL] [Abstract][Full Text] [Related]
7. HIV remission trial investigators' attitudes towards risk and risk mitigation in trials that include treatment interruption.
Okumu EA; Henderson GE; Golin C; Kuczynski K; Ormsby NQ; Peay HL
J Virus Erad; 2023 Jun; 9(2):100331. PubMed ID: 37416088
[TBL] [Abstract][Full Text] [Related]
8. Perceptions of HIV cure research among people living with HIV in Australia.
Power J; Westle A; Dowsett GW; Lucke J; Tucker JD; Sugarman J; Lewin SR; Hill S; Brown G; Wallace J; Richmond J
PLoS One; 2018; 13(8):e0202647. PubMed ID: 30142171
[TBL] [Abstract][Full Text] [Related]
9. Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment.
Henderson GE; Peay HL; Kroon E; Cadigan RJ; Meagher K; Jupimai T; Gilbertson A; Fisher J; Ormsby NQ; Chomchey N; Phanuphak N; Ananworanich J; Rennie S
J Med Ethics; 2018 Apr; 44(4):270-276. PubMed ID: 29127137
[TBL] [Abstract][Full Text] [Related]
10. Considerations for Increasing Racial, Ethnic, Gender, and Sexual Diversity in HIV Cure-Related Research with Analytical Treatment Interruptions: A Qualitative Inquiry.
Dubé K; Kanazawa J; Campbell C; Boone CA; Maragh-Bass AC; Campbell DM; Agosto-Rosario M; Stockman JK; Diallo DD; Poteat T; Johnson M; Saberi P; Sauceda JA
AIDS Res Hum Retroviruses; 2022 Jan; 38(1):50-63. PubMed ID: 33947268
[TBL] [Abstract][Full Text] [Related]
11. Going off antiretroviral treatment in a closely monitored HIV "cure" trial: longitudinal assessments of acutely diagnosed trial participants and decliners.
Henderson GE; Waltz M; Meagher K; Cadigan RJ; Jupimai T; Isaacson S; Ormsby NQ; Colby DJ; Kroon E; Phanuphak N; Ananworanich J; Peay HL
J Int AIDS Soc; 2019 Mar; 22(3):e25260. PubMed ID: 30869203
[TBL] [Abstract][Full Text] [Related]
12. Attitudes About Analytic Treatment Interruption (ATI) in HIV Remission Trials with Different Antiretroviral Therapy (ART) Resumption Criteria.
Peay HL; Rennie S; Cadigan RJ; Gwaltney A; Jupimai T; Phanuphak N; Kroon E; Colby DJ; Ormsby N; Isaacson SC; Vasan S; Sacdalan C; Prueksakaew P; Benjapornpong K; Ananworanich J; Henderson GE
AIDS Behav; 2022 May; 26(5):1504-1516. PubMed ID: 34997386
[TBL] [Abstract][Full Text] [Related]
13. Motivations, barriers and experiences of participants in an HIV reservoir trial.
De Scheerder MA; van Bilsen WPH; Dullaers M; Martinez-Picado J; Davidovich U; Vandekerckhove L
J Virus Erad; 2021 Mar; 7(1):100029. PubMed ID: 33598311
[TBL] [Abstract][Full Text] [Related]
14. Perceptions of Risks and Benefits of Participating in HIV Cure-Related Research Among Diverse Young Adults Living with HIV in the United States: Qualitative Research Findings.
Saberi P; Campbell CK; Sauceda JA; Ndukwe S; Dubé K
AIDS Res Hum Retroviruses; 2022 Aug; 38(8):649-659. PubMed ID: 35579937
[TBL] [Abstract][Full Text] [Related]
15. Perspectives on Analytical Treatment Interruptions in People Living with HIV and Their Health Care Providers in the Landscape of HIV Cure-Focused Studies.
Lau JSY; Smith MZ; Allan B; Martinez C; Power J; Lewin SR; McMahon JH
AIDS Res Hum Retroviruses; 2020 Apr; 36(4):260-267. PubMed ID: 31608648
[TBL] [Abstract][Full Text] [Related]
16. Ethical and practical considerations for mitigating risks to sexual partners during analytical treatment interruptions in HIV cure-related research.
Dubé K; Kanazawa J; Dee L; Taylor J; Campbell DM; Brown B; Johnson MO; Saberi P; Sauceda JA; Sugarman J; Peluso MJ
HIV Res Clin Pract; 2021 Feb; 22(1):14-30. PubMed ID: 33757411
[No Abstract] [Full Text] [Related]
17. Willingness to participate and take risks in HIV cure research: survey results from 400 people living with HIV in the US.
Dubé K; Evans D; Sylla L; Taylor J; Weiner BJ; Skinner A; Thirumurthy H; Tucker JD; Rennie S; Greene SB
J Virus Erad; 2017 Jan; 3(1):40-50.e21. PubMed ID: 28275457
[TBL] [Abstract][Full Text] [Related]
18. Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption.
Giron LB; Papasavvas E; Yin X; Goldman AR; Tang HY; Palmer CS; Landay AL; Li JZ; Koethe JR; Mounzer K; Kostman JR; Liu Q; Montaner LJ; Abdel-Mohsen M
mBio; 2021 Feb; 12(1):. PubMed ID: 33622719
[TBL] [Abstract][Full Text] [Related]
19. Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design.
Lau JSY; Cromer D; Pinkevych M; Lewin SR; Rasmussen TA; McMahon JH; Davenport MP
J Infect Dis; 2022 Aug; 226(2):236-245. PubMed ID: 35104873
[TBL] [Abstract][Full Text] [Related]
20. Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA.
Strongin Z; Sharaf R; VanBelzen DJ; Jacobson JM; Connick E; Volberding P; Skiest DJ; Gandhi RT; Kuritzkes DR; O'Doherty U; Li JZ
J Virol; 2018 Jun; 92(12):. PubMed ID: 29593048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
